EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10)

Ali Ekin, Salim Misirci, Nihal Lermi, Nagehan Dik Kutlu, Belkis Nihan Coskun, Burcu Yagız, Ediz Dalkılıç, Yavuz Pehlivan

Aktuelle Rheumatologie · 01.02.2025 · 50 (01) · 71-82

DOI: 10.1055/a-2403-2896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aktuelle Rheumatologie, erschienen am 01.02.2025. Verfasst von Ali Ekin und 7 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgorund Rituximab is an anti-CD20 monoclonal antibody used in the treatment of rheumatoid arthritis. The molecule CT -P10 is a biosimilar of rituximab used in rheumatoid arthritis and has the same safety and efficacy. Material and methods The aim of our study was to investigate whether drug efficacy decreases after the mandatory switch from originator rituximab to biosimilar rituximab, whether there is an increase in disease activity indices in patients with rheumatoid arthritis receiving rituximab, that could indicate decreased efficacy, and whether the frequency of adverse events related to drug safety remains comparable. We analysed 131 patients with rheumatoid arthritis who received rituximab therapy between January 2010 and December 2022.These patients were switched from the originator rituximab to biosimilar rituximab and followed up. Results After the switch, a statistically significant decrease in HAQ, DAS-28-CRP, and CDAI scores was observed, while there was no increase in disease activity in other scales. We found that the frequency of adverse events associated with originator rituximab treatment was correlated with anti-CCP positivity (OR=5.436; p=0.006), the presence of an infection requiring hospitalisation (OR=3.917; p=0.012), and the duration of first rituximab treatment (OR=1.032; p

Zitieren

APA

Ekin, A., Misirci, S., Lermi, N., Kutlu, N. D., Coskun, B. N., Yagız, B., Dalkılıç, E., & Pehlivan, Y. (2025). Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10). Aktuelle Rheumatologie, 50(01), 71-82. https://doi.org/10.1055/a-2403-2896

Vancouver

Ekin A, Misirci S, Lermi N, Kutlu ND, Coskun BN, Yagız B, et al. Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10). Aktuelle Rheumatologie. 2025;50(01):71-82. doi:10.1055/a-2403-2896

BibTeX
@article{Ekin2025,
  author = {Ekin, Ali and Misirci, Salim and Lermi, Nihal and Kutlu, Nagehan Dik and Coskun, Belkis Nihan and Yagız, Burcu and Dalkılıç, Ediz and Pehlivan, Yavuz},
  title = {Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10)},
  journal = {Aktuelle Rheumatologie},
  year = {2025},
  volume = {50},
  number = {01},
  pages = {71--82},
  doi = {10.1055/a-2403-2896}
}
Kostenlos starten →